



A flexible approach to
Neuropharmacology

OUR PROFOUND EXPERTISE IN NEUROSCIENCE AND TWO DECADES OF EXPERIENCE IN CONTRACT RESEARCH RESULTS IN A SUSTAINABLE ADVANTAGE FOR OUR CUSTOMERS. QPS offers you a sophisticated range of validated transgenic and non-transgenic *in vivo* and *in vitro* models to guarantee that your new chemical or biological compounds are profiled in depth.

TIME IS OF THE ESSENCE IN DRUG DEVELOPMENT. CONTACT THE QPS BUSINESS DEVELOPMENT TEAM TODAY!

CALL +1 512 350 2827 **EMAIL** infobd@qps.com



Profound Expertise

The QPS Neuropharmacology Team is comprised of professionals with industry and academia expertise in custom development and validation of transgenic and non-transgenic *in vivo* and *in vitro* models, providing top-of-the-line services tailored to the specific needs of our clients. Our neuropharmacologists have profound expertise and extensive hands-on experience of sophisticated projects that have addressed many new and already established drug targets in neurodegenerative diseases.

Knowledge of Neurodegenerative Diseases

There has been a tremendous burst of information about cognition and its neuronal bases during the past two decades. As new knowledge develops, there is a need to continually update the preclinical and clinical pharmacological tools that we use to assess cognition and other brain functions. Keeping those tools updated is essential for evolving an in-depth understanding of the cognitive and/or motor deficits caused by neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's disease.

State-of-the-Art Facilities

QPS has AAALAC accredited animal housing facilities and fully-equipped histology, cell culture, biochemistry and molecular biology laboratories.

The QPS Translational Neurosciences Team

The QPS Translational Neurosciences Team is familiar with the numerous treatment approaches developed for neurodegenerative diseases, and has conducted research on new drugs of every pharmacological class. Furthermore, our ADME experts have been using "drugability" screens for lead optimization to ensure higher technical success rates in selecting useful drug candidates.

Our Translational Neurosciences Team has a long track record of conducting clinical trials for numerous neurological and psychiatric disease therapies. Our clinicians are aware of the latest diagnostic criteria and the most recent developments in study design to fulfill the requirements of modern CNS research. They recognize the problems and limitations of currently available cognitive tests and are active in developing and validating new methodologies in close collaboration with key international opinion leaders. Their expertise includes complex study design with sequential CSF sampling, structural MRI, and PET.

For CSF studies, the QPS Translational Neurosciences Team supports the quantification of all relevant disease biomarkers with state-of-the-art technologies. We are also involved in developing and standardizing new biomarkers to support early diagnosis and to document precise drug effects on important disease mechanisms.

QPS is a Global CRO with locations around the world

